Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development.
In our group, we are focused on using proteomics, mass spectrometry and biochemical approaches to understand disease processes.
The group has expertise in proteomics based methodologies and hosts a platform containing a variety of chromatography equipment and mass spectrometers.
Kessler Group Sky Garden London Nov 2018
- For Non-Scientists
- Research Overview
- Mass Spectrometry
- Public Engagement
- Photo Gallery
- Virtual tour of the Kessler Lab
- Former Group Members
The deubiquitinase TRABID stabilises the K29/K48-specific E3 ubiquitin ligase HECTD1
Harris LD. et al, (2020), Journal of Biological Chemistry, jbc.RA120.015162 - jbc.RA120.015162
Detection and Quantification of Novel C‐terminal TDP‐43 Fragments in ALS‐TDP
Feneberg E. et al, (2020), Brain Pathology
CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis
Thompson AG. et al, (2020), Clinical Proteomics, 17
Subclinical effects of remote ischaemic conditioning in human kidney transplants revealed by quantitative proteomics
Thorne AM. et al, (2020), Clinical Proteomics, 17
Cytoskeletal disorganization underlies PABPN1-mediated myogenic disability
Olie CS. et al, (2020), Scientific Reports, 10